SHALBY LIMITED
SHALBY · Defence · NSE
₹154
Current Market Price
Fair Value (DCF)
₹251
Margin of Safety
+62.5%
Updated 12h ago
YieldIQ Score
55/100
Piotroski F-Score
3/9
Economic Moat
Narrow
Confidence
18%
ROE
—
Debt/Equity
0.53
WACC
11.1%
Market Cap
₹1,655 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
7.3%
Return on capital employed
EV / EBITDA
16.2×
Enterprise multiple
Debt / EBITDA
3.5×
Leverage vs earnings
Interest Coverage
2.6×
EBIT covers interest
Current Ratio
1.45×
Short-term liquidity
Asset Turnover
0.63×
Revenue per ₹ of assets
Revenue CAGR (3Y)
15.6%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹154.21
Bear case
₹151.97
MoS -1.5%
Base case
₹250.59
MoS +38.5%
Bull case
₹333.54
MoS +53.8%
Ratio Trends
SHALBY · last 8 annual periods
ROE
0.6%
ROCE
10.7%
Operating Margin
—
Debt / Equity
0.48×
PE
103.6×
EV / EBITDA
9.5×
Historical Financials
SHALBY · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹419 Cr | ₹699 Cr | ₹199 Cr | ₹244 Cr | ₹1081 Cr | +26.8% |
| EBITDA | — | ₹128 Cr | ₹158 Cr | ₹195 Cr | ₹157 Cr | +5.2% |
| EBIT | ₹59.1 Cr | ₹85.0 Cr | ₹22.0 Cr | ₹28.3 Cr | — | -16.8% |
| PAT | ₹42.9 Cr | ₹54.0 Cr | ₹13.9 Cr | ₹16.0 Cr | ₹6.2 Cr | -38.3% |
| EPS (diluted) | ₹3.97 | ₹5.00 | ₹1.29 | ₹1.49 | — | -21.7% |
| CFO | ₹82.4 Cr | ₹18.9 Cr | ₹67.8 Cr | ₹19.6 Cr | ₹-4.3 Cr | — |
| CapEx | — | — | — | — | ₹-71.4 Cr | — |
| FCF | — | — | — | — | ₹-75.8 Cr | — |
| Total Assets | — | ₹1194 Cr | ₹1281 Cr | ₹1608 Cr | ₹1704 Cr | +9.3% |
| Total Debt | — | — | ₹78.9 Cr | ₹138 Cr | ₹476 Cr | +56.7% |
| Shareholders' Equity | — | — | ₹928 Cr | ₹1000 Cr | ₹995 Cr | +1.8% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
SHALBY vs 2 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| GPTHEALTH GPT HEALTHCARE LIMITED | +38.5% | 60 | Undervalued | 20.1% | — |
| INDRAMEDCO INDRAMEDCO | — | — | Pending | 27.0% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for SHALBY in the last 10 years.
Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of SHALBY →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for SHALBY →
Compare
Head-to-head with peers
Compare SHALBY side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse SHALBYNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.